Parkinson’s disease, a debilitating neurodegenerative disorder, affects millions worldwide, characterized by the loss of dopamine-producing neurons leading to motor dysfunction and a spectrum of non-motor symptoms. Despite decades of research, teasing apart the heterogeneous nature of PD has remained a foremost challenge. The dichotomous theory posits that some patients experience an initial pathological insult in the brain (Brain-First subtype), while in others, the disease process begins in the peripheral autonomic nervous system before ascending to the brain (Body-First subtype). This crucial differentiation could tailor early intervention strategies, but has been limited by a lack of definitive biomarkers to reliably classify patients.

This new study, appearing in the prestigious journal npj Parkinson’s Disease, leverages the well-established technique of dopamine transporter single-photon emission computed tomography (DAT-SPECT). DAT-SPECT is routinely employed to visualize striatal dopaminergic integrity, serving as a surrogate marker for neurodegeneration in PD. However, solely relying on conventional DAT-SPECT metrics has not been sufficient to disentangle the proposed Brain-First versus Body-First subtypes. The innovation arises by integrating radiomics, an emerging field that extracts a large number of quantitative features from medical images using advanced computational algorithms.

Radiomics can unveil subtle patterns and textures within images imperceptible to the human eye and standard metrics. By applying radiomics-enhanced analysis to DAT-SPECT brain scans, the research team identified distinguishing signatures correlated with the two PD subtypes. These signatures capture nuanced heterogeneity in tracer uptake distribution, asymmetry, and shape characteristics of the striatal dopaminergic deficit. Such imaging phenotypes open avenues to classify individual patients more precisely and understand the underlying pathological geography.

Importantly, the study recruited a rigorously phenotyped patient cohort, encompassing newly diagnosed PD individuals along the suggested Brain-First and Body-First trajectories. The researchers validated their radiomics-based classification model against conventional visual and semi-quantitative assessments, demonstrating superior performance in discriminating subtypes. This breakthrough underscores the potential of combining conventional nuclear imaging with high-dimensional radiomic feature extraction to enhance diagnostic granularity, paving the way for personalized medicine in Parkinson’s.

Delving into the methodology, raw DAT-SPECT images underwent meticulous preprocessing to standardize spatial and intensity parameters, ensuring robustness across multi-center datasets. From the processed images, over one hundred radiomic features were extracted encompassing first-order statistics, shape, texture, and intensity-based metrics. Advanced machine learning algorithms were employed to identify the most discriminative features, culminating in an optimized classifier that markedly separated Brain-First and Body-First phenotypes with statistical rigor.

The implications of these findings extend beyond diagnosis alone. Accurately identifying PD subtypes at early stages can inform prognosis, as the Brain-First and Body-First forms differ not only in initial symptomatology but also in progression rate, cognitive involvement, and response to therapies. For instance, Body-First patients frequently experience pronounced autonomic dysfunction and REM sleep behavior disorder, whereas Brain-First patients show earlier cognitive impairment. Tailored monitoring protocols and therapeutic regimens could therefore improve patient outcomes substantially.

Moreover, this work holds promise for unraveling the pathogenic mechanisms that have long eluded the scientific community. The ability to label patients according to their disease origin supports hypotheses about distinct spreading patterns of alpha-synuclein pathology, the hallmark protein aggregate driving PD. Brain-First cases may reflect central neurodegeneration originating within substantia nigra neurons, while Body-First forms could represent peripheral-to-central propagation. Mapping these pathways with imaging aids in targeting disease-modifying treatments to the site of earliest involvement.

The radiomics-enhanced DAT-SPECT approach also advances the field of biomarker research in neurodegeneration, exemplifying how machine learning and quantitative image analysis can overcome limitations of conventional interpretation. As large international consortia collect extensive multimodal imaging and clinical datasets, such integrative analytic techniques will accelerate biomarker discovery, validation, and clinical adoption, transforming the diagnostic landscape.

Despite its promise, the research team acknowledges remaining challenges before widespread clinical translation. Larger multicenter studies are necessary to confirm replicability and generalizability across diverse populations and imaging platforms. Longitudinal investigations will elucidate how imaging phenotypes evolve over disease course and whether they predict therapeutic responses. Additionally, incorporation of complementary modalities such as MRI and peripheral biomarkers could refine subtype stratification further.

Nonetheless, this study represents a seminal leap forward in differentiating PD subtypes through sophisticated imaging analytics. By harnessing the synergy of radiomics and DAT-SPECT, clinicians now possess a powerful tool to unmask the heterogeneity underlying Parkinson’s disease, bringing precision neurology within reach. As this paradigm expands, it could catalyze new avenues for early intervention, pathophysiological understanding, and ultimately, personalized care to improve lives guarded by this relentless disorder.

The researchers envision future integration of their radiomics-based classifier into routine nuclear medicine workflows. This would enable prompt subtype identification immediately after diagnostic imaging, facilitating tailored clinical decision-making. Combined with emerging disease-modifying agents and symptomatic therapies, personalized management strategies targeting Brain-First or Body-First subgroups could revolutionize standard PD care.

In conclusion, the study published by Palermo and colleagues signals an exciting juncture in Parkinson’s research, showcasing the power of cutting-edge image analysis to clarify a major unresolved question in the field. The capacity to discriminate Brain-First from Body-First PD using conventional and radiomics-enhanced DAT-SPECT images sets the stage for fundamentally improving diagnostic accuracy, patient stratification, and targeted treatment approaches. This paradigm shift illustrates how artificial intelligence and quantitative imaging can transform clinical neuroscience, offering renewed hope in the battle against Parkinson’s disease.

Subject of Research: Differentiation of Brain-First and Body-First Parkinson’s disease subtypes using dopamine transporter SPECT imaging and radiomics.

Article Title: Discriminating between proposed Brain-First and Body-First Parkinson’s disease using conventional and radiomics-enhanced dopamine transporter SPECT image analysis.

Article References:
Palermo, G., Aghakhanyan, G., Bellini, G. et al. Discriminating between proposed Brain-First and Body-First Parkinson’s disease using conventional and radiomics-enhanced dopamine transporter SPECT image analysis. npj Parkinsons Dis. 11, 328 (2025). https://doi.org/10.1038/s41531-025-01164-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41531-025-01164-z

Parkinson’s disease, characterized primarily by motor dysfunctions such as tremors, bradykinesia, and rigidity, also presents a broad spectrum of non-motor symptoms, including cognitive decline and mood disorders. These symptoms contribute substantially to the disease burden. The study delves deeply into the potential modulatory role of peripheral inflammatory markers, which historically have been linked to numerous chronic conditions but whose exact impact in PD has remained elusive. The authors employ both longitudinal and cross-sectional analytical techniques, enabling them to track inflammatory effects over different time scales and symptom domains.

A critical takeaway from this research lies in its pioneering approach to dissect peripheral inflammation’s heterogenous impact on various clinical outcomes in PD. Unlike previous studies that often treated inflammation as a monolithic factor, this investigation reveals a more complex, variable influence contingent upon individual patient profiles, disease stages, and symptom severity. Such variability challenges conventional treatment paradigms and highlights the necessity for personalized therapeutic strategies targeting inflammatory pathways.

The researchers utilized a robust cohort comprising PD patients at varied stages of illness alongside matched controls, collecting longitudinal data that included inflammatory biomarkers such as cytokine levels measured in plasma and cerebrospinal fluid. Cognitive assessments were rigorously standardized, integrating tools sensitive enough to detect subtle changes in domains like executive function, memory, and attention. Symptom progression was monitored through validated scales, facilitating a comprehensive overview of Parkinsonian symptomatology.

One of the most striking findings reported was the differential association between peripheral inflammation and specific cognitive domains. Elevated levels of pro-inflammatory cytokines correlated strongly with declines in executive function and working memory but less so with visuospatial abilities. This selective vulnerability hints at underlying neuroimmune mechanisms that may preferentially affect certain neuronal circuits, possibly through the disruption of blood-brain barrier integrity or the activation of microglial cells within critical brain regions.

Moreover, the study elaborated on the temporal dynamics of these inflammatory effects. In the cross-sectional analysis, high peripheral inflammation was associated with more severe motor symptoms and poorer cognitive performance at baseline. However, the longitudinal data revealed that inflammation predicted cognitive decline trajectories differently among individuals, suggesting that inflammation’s impact may amplify or attenuate depending on disease progression and patient-specific inflammatory profiles.

An intriguing aspect of this research is the discussion on symptomatic heterogeneity in Parkinson’s disease. The authors challenge the notion of a uniform disease course by demonstrating how inflammation interacts with genetic and environmental factors to create diverse symptomatic landscapes. This interplay underscores the potential for biomarkers like cytokines to stratify patients and tailor interventions aimed at modulating immune responses to slow or alter disease progression.

From a mechanistic perspective, the authors explore the pathophysiological pathways linking peripheral inflammation to neurodegeneration in PD. Chronic systemic inflammation is postulated to facilitate neuroinflammatory cascades that exacerbate alpha-synuclein aggregation, a hallmark of Parkinson’s pathology. Additionally, peripheral immune activation may promote oxidative stress and mitochondrial dysfunction, further driving neuronal loss. These insights broaden the conceptual framework of PD as not solely a neurocentric disorder but a multisystem disease influenced by systemic immune status.

The corrected article also addresses methodological limitations encountered in previous studies, such as sample size constraints and inconsistent biomarker measurement techniques. The current study’s rigorous approach, with its well-characterized cohorts and comprehensive longitudinal data, allows for more definitive conclusions about causality and temporal relationships between inflammation and clinical outcomes. This methodological robustness strengthens the argument for incorporating peripheral inflammatory markers into routine clinical assessment of PD.

Clinically, these findings open avenues for novel therapeutic targets. Anti-inflammatory agents, some of which are already FDA-approved for other conditions, may be repurposed as adjunct treatments for PD to mitigate cognitive decline and improve quality of life. The variability in inflammatory impact observed demands a precision medicine approach, wherein patient-specific inflammatory profiles guide the selection and timing of such interventions.

Another aspect highlighted by the study is the potential predictive value of inflammatory biomarkers. Early identification of patients at risk for rapid cognitive decline or severe motor worsening could revolutionize disease management. For instance, routine screening of peripheral cytokine levels may become integral to personalized monitoring protocols, enabling timely adjustments in treatment regimens aimed at curbing inflammation-driven neurodegeneration.

In summary, this landmark study by He and colleagues significantly advances our grasp of how peripheral inflammation serves as a critical, yet complex, modulator of Parkinson’s disease progression. Its insights not only refine the current pathophysiological model of PD but also pave the way for innovative diagnostic and therapeutic strategies. As the scientific community continues to unravel the immune system’s role in neurodegeneration, such detailed investigations will be indispensable for translating research breakthroughs into tangible clinical benefits.

The article’s publication in a leading Parkinson’s-focused journal reflects the growing recognition of inflammation’s importance across neurodegenerative diseases. Its findings invite a paradigm shift from viewing Parkinson’s as solely a CNS disorder to acknowledging the systemic interactions shaping its course. This integrated understanding impels future research to expand beyond neural mechanisms to encompass peripheral immune processes.

Ultimately, the multifaceted relationship between peripheral inflammation and Parkinson’s symptoms exemplifies the complexity inherent in neurodegenerative conditions. By embracing this complexity, researchers and clinicians may better design interventions that address not just the symptoms but the underlying mechanisms driving disease heterogeneity. This comprehensive approach holds profound promise for improving patient outcomes and mitigating the heavy societal burden of Parkinson’s disease.

Subject of Research: The variable impact of peripheral inflammation on cognitive decline and symptomatic outcomes in Parkinson’s disease analyzed through longitudinal and cross-sectional studies.

Article Title: Author Correction: Peripheral inflammation’s variable impact on cognitive and symptomatic outcomes in Parkinson’s disease: a longitudinal and cross-sectional analysis.

Article References: He, P., Li, Y., Huang, Z. et al. Author Correction: Peripheral inflammation’s variable impact on cognitive and symptomatic outcomes in Parkinson’s disease: a longitudinal and cross-sectional analysis. npj Parkinsons Dis. 11, 309 (2025). https://doi.org/10.1038/s41531-025-01176-9

Image Credits: AI Generated